(Total Views: 366)
Posted On: 12/16/2019 9:59:24 AM
Post# of 156338
Re: LaundryMoney #12763
American Association for Cancer Research states:
“We estimate that by January 1, 2017, there will be 154,794 women living with MBC in the United States, three in four initially diagnosed with stage I–III breast cancer who later progressed to MBC.”
Now if Leronlimab can treat half these metastatic breast cancer patients we have 77,000 patients x $50,000 = 3.85 billion at 8x would establish a 30.8 billion dollar buy out price at 700,000,000 shares outstanding that’s $44/share. We should start here and add prostate, liver, lung colon, and melanoma! Now we’re talking buy out! NASH and I forgot HIV?
“We estimate that by January 1, 2017, there will be 154,794 women living with MBC in the United States, three in four initially diagnosed with stage I–III breast cancer who later progressed to MBC.”
Now if Leronlimab can treat half these metastatic breast cancer patients we have 77,000 patients x $50,000 = 3.85 billion at 8x would establish a 30.8 billion dollar buy out price at 700,000,000 shares outstanding that’s $44/share. We should start here and add prostate, liver, lung colon, and melanoma! Now we’re talking buy out! NASH and I forgot HIV?
(1)
(0)
